GTF3C4

Across TCGA pan-cancer cohorts, GTF3C4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GTF3C4 data layer compared with 19 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher GTF3C4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GTF3C4 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

OV, COAD, and KICH are the cancer types where GTF3C4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.326	0.694	<.001	36	view →
COAD	OS	Median	All	0.143	0.614	.007	18	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
BLCA	DFS	Median	IV	1.000	0.307	.031	6	view →
UCEC	DFS	Median	All	0.964	0.829	.032	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GTF3C4–OV (OS)

Open the OV breakdown →